NCT00885833View on ClinicalTrials.gov

Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Wiskott-Aldrich Syndrome
Interventions
DRUG

Fludarabine, Busulfan, Thymoglobulin

fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 \& -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, \& -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, -6 for cord blood and on days -4, -3, -2 for bone marrow or mobilized peripheral blood)

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

The Korean Society of Pediatric Hematology Oncology

NETWORK

NCT00885833 - Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS) | Biotech Hunter | Biotech Hunter